# Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases

> **NCT00807170** · PHASE1 · TERMINATED · sponsor: **Sanofi** · enrollment: 5 (actual)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** ZD6474 (Vandetanib)
- **RADIATION:** Whole Brain Radiotherapy (WBRT)
- **DRUG:** ZD6474
- **DRUG:** ZD6474

## Key facts

- **NCT ID:** NCT00807170
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-05
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Very slow recruitment
- **Last updated:** 2016-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00807170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00807170, "Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00807170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*